Monika Engelhardt

Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years

Monika Engelhardt, Gabriele Ihorst, Ola Landgren et al. · Haematologica · 2015 · 51 citations · Full text

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Marc S. Raab, Niels Weinhold, K. Martin Kortüm et al. · Blood · 2024 · 31 citations

Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma

Andrea Keppler‐Hafkemeyer, Christine Greil, Paul R. Wratil et al. · Nature Cancer · 2022 · 27 citations · Full text

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma

Christian Straka, Kerstin Schaefer-Eckart, Bernd Hertenstein et al. · Blood · 2022 · 16 citations · Full text

Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma

Marc S. Raab, Manik Chatterjee, Hartmut Goldschmidt et al. · Blood · 2015 · 12 citations